Pharming Group to participate in February investor conference

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of February:

• Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025
  Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.

For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Oppenheimer representative.
 

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: [email protected]

FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: [email protected]

Attachment

• Pharming attending Investor Conferences February 2025_EN_10FEB25

You May Also Be Interested In

• Appointment of Non-Executive Directors
• Additional Information on the Ehrmann Family Increasing Its Equity Stake in Artprice by Artmarket as Part of Artprice's "AI-First" Transformation
• Top Meme Coin To Buy: Pipedog Selling Persists Despite 3,294% APY as AlphaPepe Stage 20 Keeps Filling